Anticoagulation therapy in Chinese patients with non-valvular atrial fibrillation: A prospective, multi-center, randomized, controlled study

Chinese Medical Journal

Volumn 125, Issue 24, 2012, Pages 4355-4360

  Chen, Ke Ping ^a   Huang, Cong Xin ^b   Huang, De Jia ^c   Cao, Ke Jiang ^a   Ma, Chang Sheng ^d   Wang, Fang Zheng ^a   Zhang, Shu ^a  

^a FUWAI HOSPITAL   (China)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Anticoagulation; Chinese; Nonvalvular atrial fibrillation

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHINESE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EYE TOXICITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; MULTICENTER STUDY; NOSE DISEASE; PHYSICAL EXAMINATION; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN TOXICITY; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; WARFARIN;

EID: 84874326484     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.24.007     Document Type: Review

References (15)

1. Petersen P, Boy sen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175-179. (Pubitemid 19038801)
2. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-1511.
3. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study final results. Circulation 1991; 84: 527-539.
4. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-1412.
5. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J AM Coll Cardiol 1991; 18: 349-355.
6. Yamaguchi T. For Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Optimal intensity of wafarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Stroke 2000; 31: 817-821. (Pubitemid 30198421)
7. Zhou ZQ, Hu DY, Chen J, Zhang RH, Li KB, Zhao XL. An epidemiological survey of atrial fibrillation in China. Chin J Intern Med (Chin) 2003; 43:491-494.
8. Atrial Fibrillation Investigator. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
9. Hu DY. The efficacy and safety of antithrombotic therapy with warfarin in nonrheumatic atrial fibrillation. Chin J Intern Med (Chin) 2006; 45: 800-803.
10. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. Warfarin-Aspirin Recurrent Stroke Study Group. N Engl J Med 2001; 345:1444-1451.
11. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001; 40: 1183-1188. (Pubitemid 34110494)
12. Hu DY, Sun YH, Zhou ZQ, Li KB, Ni YB, Yang G, et al. Rusk facts for stroke in Chinese with non valvular artrial fibrillation: a case-control study. Chin J Intern Med (Chin) 2003; 42: 157-161.
13. Ma CS, Zhou YJ, Ma Y, Zheng ZG, Yang HB, Wang Y, et al. A follow-up study of incidence of stroke and risk factors in patients with nonvalvular atrial fibrillation in Beijing area. Chin J Cardiol (Chin) 2002; 30: 165-167.
14. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation 2006; 114:700-752.
15. Warm LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011; 57: 1330-1337.